Can nivolumab fight blood cancers that come back after CAR t?
NCT ID NCT04205409
First seen Nov 03, 2025 · Last updated Jun 11, 2026 · Updated 27 times
Summary
This study tested the drug nivolumab in 20 adults with blood cancers (like lymphoma, leukemia, or myeloma) that returned or did not respond after CAR T-cell therapy. Nivolumab is an immunotherapy that helps the body's immune system attack cancer cells. The goal was to see if it could shrink tumors or slow the disease, but it is not a cure—patients may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.